Hummingbird Bioscience Information

Hummingbird Bioscience is a clinical-stage biotherapeutics company integrating AI and rigorous experimental science to bring more precise, scientifically grounded medicines to patients faster. Its lab-in-the-loop AI Molecular Medicine platform, AIMM, draws on over a decade of proprietary experimental, translational, and clinical data, learning from every new data point to prioritize hypotheses, select targets and indications, and design and optimize biotherapeutics. By combining AI with biological expertise and wet-lab validation, Hummingbird Bioscience has advanced several programs from concept to clinic in 12 months. Hummingbird Bioscience has engineered a deep pipeline with AIMM, including four programs in clinical trials and seven programs out-licensed or partnered. Sign up for our updates here: https://bit.ly/HMBDNews